Clinical Trial: A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07195682) titled 'A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)' on Sept. 25.

Brief Summary: This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.

Study Start Date: Dec. 15, 2025

Study Type: INTERVENTIONAL

Condition: Renal Cell Carcinoma

Intervention: DRUG: BMS-986506

Specified dose on specified days

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Bristol-Myers Squibb

Published by H...